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Estrogen rescues heart failure through
estrogen receptor Beta activation
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Rangarajan D. Nadadur1, Jean C. Bopassa1,4 and Mansoureh Eghbali1*
Abstract
Background: Recently, we showed that exogenous treatment with estrogen (E2) rescues pre-existing advanced
heart failure (HF) in mice. Since most of the biological actions of E2 are mediated through the classical estrogen
receptors alpha (ERα) and/or beta (ERβ), and both these receptors are present in the heart, we examined the role
of ERα and ERβ in the rescue action of E2 against HF.
Methods: Severe HF was induced in male mice by transverse aortic constriction-induced pressure overload. Once
the ejection fraction (EF) reached ~ 35%, mice were treated with selective agonists for ERα (PPT, 850 μg/kg/day),
ERβ (DPN, 850 μg/kg/day), or E2 (30 μg/kg/day) together with an ERβ-antagonist (PHTPP, 850 μg/kg/day) for
10 days.
Results: EF of HF mice was significantly improved to 45.3 ± 2.1% with diarylpropionitrile (DPN) treatment, but not
with PPT (31.1 ± 2.3%). E2 failed to rescue HF in the presence of PHTPP, as there was no significant improvement in
the EF at the end of the 10-day treatment (32.5 ± 5.2%). The improvement of heart function in HF mice treated with
ERβ agonist DPN was also associated with reduced cardiac fibrosis and increased cardiac angiogenesis, while
the ERα agonist PPT had no significant effect on either cardiac fibrosis or angiogenesis. Furthermore, DPN
improved hemodynamic parameters in HF mice, whereas PPT had no significant effect.
Conclusions: E2 treatment rescues pre-existing severe HF mainly through ERβ. Rescue of HF by ERβ activation is also
associated with stimulation of cardiac angiogenesis, suppression of fibrosis, and restoration of hemodynamic
parameters.
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Background
Heart hypertrophy is usually triggered by external
stressors. While it is presumed to be compensatory at
the beginning, it often progresses to chronic heart failure
(HF) if the external stimulus persists. HF is characterized
by the progressive loss of contractility of the myocar-
dium, leading to diminished cardiac output [1]. Female
sex is a significant independent predictor of survival in
patients with congestive HF [2], and women with ad-
vanced HF appear to have better survival outcome than
men [3]. Estrogen has been shown to confer
cardioprotection in experimental models of HF [4, 5].
Pre-treatment with E2 reduced the extent of pressure
overload-induced hypertrophy and attenuated the deteri-
oration of left ventricular (LV) systolic function and con-
tractility [6]. We have also shown recently that E2 is
even able to rescue pre-existing HF [5]. Estrogen mainly
acts through classical estrogen receptor alpha (ERα)
and/or estrogen receptor beta (ERβ), and both receptors
are present in the heart [7, 8]. The beneficial role of ERβ
in cardioprotection has been highlighted in the recent
years [4, 9, 10]. Female mice lacking ERβ are less pro-
tected against myocardial ischemia/reperfusion injury
compared to wild-type female mice. Furthermore, ERβ
knockout mice have abnormal vascular function and
hypertension, increased mortality, and aggravated heart
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failure [11]. Activation of ERβ has also been shown to
confer the anti-hypertrophic effects of E2 [10].
Increased cardiac angiogenesis is a key event in main-
taining LV function during adaptive hypertrophy induced
by pressure overload; however, the imbalance between
cardiac growth and neoangiogenesis eventually leads to
the transition from compensated heart hypertrophy to
HF [12]. Estrogen has previously been shown to be
pro-angiogenic in various tissues [2–4, 11–15]. Recently,
we have shown that E2 stimulates angiogenesis in the
heart in the LV failure model induced by pressure over-
load as well as in right ventricular failure induced by
pulmonary hypertension [4, 5].
Cardiac remodeling in HF is known to be associated
with fibrosis, which leads to stiffening of the cardiac
muscle and myocyte electrical uncoupling, thus imped-
ing both contraction and relaxation of the heart. E2 is
known to reduce adverse extracellular matrix remodel-
ing in LV hypertrophy and failure by decreasing collagen
deposition and metalloproteinase expression [16]. We
have recently shown that E2-induced rescue of HF is as-
sociated with the reversal of LV fibrosis as well as down-
regulation of pro-fibrotic genes such as collagen I/III,
transforming growth factor-β1 (TGF-β1), fibrosin I, and
lysil oxidase (LOX) to levels similar to controls [5].
Although various recent studies have investigated the
role of sex differences and E2 in the rescue of advanced
HF [5, 17, 18], the precise contribution of the major es-
trogen receptors in the E2-induced rescue of HF has not
been fully elucidated. Here, we investigated the role of
ERα and ERβ in the rescue of HF by E2. We used the
well-established transverse aortic constriction (TAC)
model to induce HF in mice and show that short-term
therapy with an ERβ-agonist, but not ERα-agonist, starting
at a late stage of HF reverses the myocardial contractile
dysfunction by significantly improving EF from 33 to ~
45%. This improvement of myocardial contractility by
ERβ was associated with increased cardiac angiogenesis,
reduced cardiac fibrosis together with downregulation of
pro-fibrotic gene expression and decreased hypertrophy.
Methods
Animals
Wild-type male CD-1 mice (3–4 months old) from
Charles River were used for the study. All protocols re-
ceived institutional review and committee approval from
the Division of Laboratory Animal Medicine (DLAM)
at UCLA. Mice were housed at DLAM with ad libitum
regular chow and water access.
Anesthesia and analgesia
For sham or TAC surgery, as well as terminal
catheterization and euthanasia, mice were anesthetized
with ketamine (100 mg/kg, intraperitoneally) and xylazine
(10 mg/kg, intraperitoneally). For echocardiography, mice
were induced with 3% isoflurane in an induction
chamber and then transferred to an anesthesia mask
(Kent Scientific) and imaged under 1.5% isoflurane
and continuous O2.
Experimental protocol
After a 1-week acclimation period, healthy mice with an
ejection fraction (EF) of ~ 60% were randomly subjected
to sham or TAC surgery as described previously [5, 19].
Serial echocardiography was performed to monitor the
heart structure and function throughout the course of
the experiment. HF was achieved 6 to 8 weeks after the
TAC surgery with an ejection fraction of ~ 35%. In this
study and our previous study, we used the outbred CD-1
strain [5], which has more genetic variability and is of
closer resemblance to clinical applications. Since the
CD-1 strain is not the common strain used in cardiac re-
search, we have performed serial echocardiography to
ensure that these mice indeed reach HF. Our findings
have also have been validated in C57BL/6 mice, the most
commonly used strain of mice [5]. We found that
the CD-1 strain is more resistant to the banding, thus
taking 6–8 weeks to reach HF versus approximately
4 weeks as in the case of the C57BL/6 strain.
Once TAC mice reached HF, they were assigned to
one of the following treatment groups for 10 days: a se-
lective ERα-agonist PPT (4,4′,4″-(4-propyl-[1H]-pyrazo-
le-1,3,5-triyl) trisphenol, 850 μg/kg/day, Tocris, PPT
group), a selective ERβ-agonist DPN (diarylpropionitrile,
850 μg/kg/day, Tocris, DPN group), and E2 (30 μg E2/kg
per day, Innovative Research of America) together with
a specific ERβ-antagonist PHTPP (4-[2-phenyl-5,7-bis(-
trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol,
850 μg/kg/day, Tocris (E2+ ERβ Antagonist). Dosages of
E2, DPN, PPT, and PHTPP were selected based on our
prior work [4, 5].
Cardiac hemodynamics
Serial B-mode and M-mode echocardiography was per-
formed using a VisualSonics (Vevo 2100) equipped with
a 30-MHz linear transducer to accurately monitor the
stage of the disease by measuring cardiac hemodynamic
parameters and heart structure. The EF of control
(CTRL) (mice prior to TAC or sham surgery) mice has
recently been reported as part of a larger study in the
Journal of the American Heart Association [5]. Cardiac
hemodynamic parameters were acquired from mechan-
ically ventilated mice under anesthesia (ketamine/xyla-
zine, 100/10 mg/kg, intraperitoneally) via direct left
ventricular catheterization in an open-chest procedure
by inserting a catheter (1.4F Millar SPR-671) connected
to a pressure transducer (Power Lab, ADInstruments)
into the LV right before euthanasia. The left ventricular
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systolic pressure (LVSP), left ventricular end-diastolic
pressure (LVEDP), and heart rate (HR) were recorded,
and the left ventricular developed pressure (LVDP) and
rate pressure product (RPP) were calculated as LVDP =
LVSP − LVEDP and RPP = HR × LVDP. The maximum
rates of the LV pressure rise (dP/dtmax) and decline
(−dP/dtmin) were directly calculated from the recordings
(Table 1). Hemodynamic data of CTRL (sham-operated
mice) and HF mice has also previously been reported by
our group [5]. Mice were euthanized by exsanguination
under deep anesthesia.
Real-time qPCR
RNA was extracted from whole ventricles snap frozen in
liquid nitrogen using the Trizol method (Invitrogen),
and cDNA synthesis was achieved using the Omniscript
RT kit (Qiagen) according to the manufacturer’s proto-
col. Real-time qPCR was performed using IQ SYBR
Green supermix (BioRad) in a final volume of 25 μL
using a BioRad CFX RT-qPCR machine. For all assays,
there were at least three samples/group assayed in dupli-
cate. Threshold cycle (Cq value) was determined using
CFX Manager, and the Cq value of the gene of interest
was normalized to the Cq value of its own internal con-
trol gene (GAPDH). Controls consisted of the reaction
cocktail without reverse transcriptase and H2O instead
of cDNA tested by RT-qPCR.
Prior to the RT-qPCR experiments, each primer set was
validated to ensure that it yields a single sharp peak in the
RT-qPCR melting curve. The controls for each primer set
consisted of the reaction cocktail without reverse tran-
scriptase and H2O instead of cDNA tested simultaneously
by RT-qPCR. All the RT-qPCR products, including the
negative controls, were then subjected to gel electrophor-
esis to ensure amplification of a single product of the ex-
pected molecular size without any product amplified in
the negative control reactions. Primer sequences were as
follows: TGF-β1—forward 5′-CCTGCAAGACCATC
GACATGG-3′ and reverse 5′-TGGTTTTCTCATAG
ATGGCGTT-3′; ANF—forward: 5′-CTGATGGATTTCA
AGAACCTGCT-3′ and reverse: 5′-CTCTGGGCTCCA
ATCCTGTC-3′; collagen I—forward 5′-GACCGATGG
ATTCCCGTTCGA-3′ and reverse 5′-AAGGTCAGC
TGGATAGCGACAT-3′; collagen III—forward 5′-AATT
CTGCCACCCCGAACTCAA-3′ and reverse 5′-TCCA
TCTTGCAGCCTTGGTTAG-3′; fibrosin I (FBRS)—for-
ward 5′-AACACGAACCCTGAGCTGCCA-3′ and re-
verse 5′-TCATGTAAGCCACACGAACGTG-3′; GAPDH
—forward 5′-CCTGCACCACCAACTGCTTAG-3′ and
reverse 5′-ATGACCTTGCCCACAGCCTTG-3′; lysil
oxydase (LOX)—forward 5′-CACGCAGCAGCAGAATG
GGC-3′ and reverse 5′-CGCAGTACCAGCCTCAGCG
A-3′; and TGF-β1—forward 5′-CCTGCAAGACCATC
GACATGG-3′ and reverse 5′-TGGTTTTCTCATAGAT
GGCGTT-3′.
Cell culture
Co-culture of neonatal rat ventricular myocytes (NRVM)
and fibroblasts were isolated as previously described
[20]. Cells were serum-starved for 24 h and then were
serum-replenished and either left untreated (CTRL) or
treated with angiotensin II (AngII, 100 nM, Sigma) in
the absence or presence of E2 (10 nM), DPN (10 nM),
or PPT (10 nM).
Immunohistochemistry and imaging
Whole hearts were fixed in 4% paraformaldehyde, and
transversal 6–7 μm sections were obtained with a cryo-
stat. Tissue sections were used for Masson Trichrome
staining (Sigma) according to the manufacturer’s proto-
col to evaluate fibrosis, and images were acquired with a
light microscope (Nikon). For immunofluorescence
staining, the heart cross sections (6 μm) were labeled
with anti-CD-31 antibody (Millipore (04-1074), 1:200 di-
lution) and wheat germ agglutinin (WGA, Invitrogen,
1:500 dilution), and images were acquired with a con-
focal scanning microscope (Nikon). Quantification of
angiogenesis and fibrosis was performed using ImageJ.
Table 1 Estrogen receptor beta activation improves cardiac hemodynamics
Ctrl (n = 10) TAC (n = 7) ERβ (n = 7) ERα (n = 5)
LVSP (mmHg) 104.7 ± 3.9 95.6 ± 5.5 129.4 ± 9.1 86.6 ± 21
LVEDP (mmHg) 6.9 ± 3.8 9.5 ± 4.9 5.2 ± 3.3 32.9 ± 24.0
LVDP (mmHg) 97.8 ± 3.8 86.2 ± 2.7 124.2 ± 7.1*^ 101.9 ± 8.0
HR 622.8 ± 19.0 421.7 ± 40.4** 520.2 ± 47.1 388.0 ± 22.4**
RPP 60,868.6 ± 2412.8 36,251.9 ± 3531.7* 62,260.7 ± 5963.43^$ 39,147.7 ± 2905.6*
dP/dtmax 11,036.6 ± 495.2 4871.4 ± 511.9** 6405.7 ± 641.2**
^ 4777.4 ± 202.8**
dP/dtmin 8390.9 ± 469.3 4429.2 ± 280.1* 4248.5 ± 1660.6**
^^ 3991.9 ± 196.5**
*P < 0.05 vs. CTRL
**P < 0.001 vs. CTRL
^P < 0.05 vs. HF
^^P < 0.001 vs. HF
$P < 0.05 vs. PPT
Iorga et al. Biology of Sex Differences            (2018) 9:48 Page 3 of 11
Statistical analysis
One-way ANOVA with Holm-Sidak post hoc tests
were used to compare between groups. P values less
than 0.05 were considered statistically significant.
Values are expressed as mean ± SEM.
Results
Estrogen improves cardiac contractility in HF mice mainly
via estrogen receptor beta
Recently, we reported that E2 rescues pre-existing HF in
mice by restoring the ejection fraction (EF) of HF mice
from 33.2 ± 1.1% in HF to 53.1 ± 1.3% within 10 days of E2
treatment. We have further showed that this protection is
conferred on C57BL/6 mice to a similar degree, as their EF
after 10 days of E2 treatment was 56.24 ± 2.40% [5]. Most
of the biological actions of E2 are mediated through ERα
or ERβ, and both of these receptors are present in the
heart [8]. Here, we examined the role of ERα and ERβ in
the rescue action of E2 against HF. Serial echocardiog-
raphy revealed that the EF of mice treated with the
ERβ-agonist DPN significantly improved (from 33.2 ± 1.2%
to 45.3 ± 2.1%, n = 7), while there was no improvement in
the EF of HF mice treated with ERα-agonist PPT (from
33.0 ± 1.5% to 31.1 ± 2.3%, n = 6, Fig. 1). Similarly, frac-
tional shortening improved only in DPN-treated mice
from 15.8 ± 0.6% to 21.9 ± 1.6% in DPN (P < 0.001, n = 7)
vs. from 15.8 ± 0.8% to 14.7 ± 1.2% in PPT (n = 6). To fur-
ther investigate the involvement of ERβ in the rescue ac-
tion of E2, some HF mice were treated with E2 in the
presence of the ERβ-antagonist PHTPP. E2 failed to rescue
HF in the presence of PHTPP, as there was no significant
improvement in their EF at the end of 10-day treatment
(from 31.5 ± 1.1% to 32.5 ± 5.2%, n = 4, Fig. 1a, b).
Anti-hypertrophic action of E2 is mediated through ERβ
To examine the effect of PPT and DPN on cardiac
hypertrophy, heart weight to body weight (HW/BW)
ratio was first measured. Treatment with DPN was asso-
ciated with decreased cardiac hypertrophy as demon-
strated by a significantly decreased HW/BW ratio to
6.84 ± 0.35 from 10.15 ± 0.30 in HF (Fig. 2a), while PPT
had no effect as the HW/BW of the PPT-treated animals
was not different than that of the HF group (9.17 ± 0.32).
The decreased in HW/BW ratio with DPN was mainly
due to the reduction in myocyte cross-sectional diameter
(CSD) as DPN administration was able to drastically re-
duce the CSD from 3.01 ± 0.40 in HF to 1.80 ± 0.16
(Fig. 2b), while PPT had only partial effect in reducing
CSD to 2.37 ± 0.13. While the ERα agonist PPT had an
effect in downregulating ANF transcript levels, DPN
significantly restored ANF transcripts to levels similar
to CTRL (from 24.27 ± 6.25 in HF to 0.84 ± 0.16 with
DPN, Fig. 2c).
Estrogen attenuates cardiac fibrosis in HF mainly via
estrogen receptor beta
We recently reported that E2-induced rescue of HF is
associated with reversal of cardiac fibrosis [5]. Here, we
examined the role of ERα and ERβ activation in cardiac
fibrosis on mice with pre-existing HF. We found that
DPN therapy attenuates both interstitial and perivascular
fibrosis, while the ERα-specific agonist PPT is not as ef-
fective (Fig. 3a, b). As previously reported, HF was asso-
ciated with widespread cardiac fibrosis. Here, we report
that the ERβ agonist was able to significantly attenuate
fibrotic scarring to 6.67 ± 1.76% from 54.25 ± 1.80% ob-
served in HF, while PPT had a partial effect (20.00 ±
2.31%). To investigate the mechanism through which
DPN can exert its beneficial actions on attenuating fi-
brosis, we assessed the transcript levels of several fi-
brotic markers. RT-qPCR revealed that the transcript
levels of several profibrotic markers were significantly
upregulated in HF (from 1.00 ± 0.29 to 2.03 ± 0.05 for
collagen I; 1.00 ± 0.07 to 2.05 ± 0.36 for collagen III; 1.00
A B
Fig. 1 ERβ-agonist, but not ERα-agonist, significantly improves HF. a Examples of M-mode images of the parasternal short axis view by
echocardiography before surgery (CTRL), in heart failure (HF) and 10 days after treatment with an ERα-agonist (PPT, left panels), ERβ-agonist (DPN,
center panels), or E2 together with the ERβ-specific antagonist PHTPP (right panels). b Averaged EF as a function of time in PPT (triangles, n = 6),
DPN (diamonds, n = 7), and E2+PHTPP (circles, n = 4). $P < 0.05 vs. PPT and $$P < 0.001 vs. PPT
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± 0.07 to 1.87 ± 0.12 for TGF-β1; 1.0 ± 0.5 to 3.6 ± 0.2 for
fibrosin I and 1.0 ± 0.08 to 10.59 ± 2.84 for LOX), and
DPN treatment significantly restored all these transcripts
to levels comparable to the CTRL (sham-operated)
group (Fig. 3c–g).
Consistent with our in vivo findings, E2 and DPN
treatments were able to reverse AngII-induced tran-
script upregulation of collagen I and TGF-β1 in a
co-culture of neonatal rat fibroblasts and ventricular
myocytes, while PPT was only partially effective in re-
ducing the levels of TGF-β1 but had no effect on col-
lagen I expression (Fig. 4a, b).
Estrogen receptor beta, but not alpha, activation is
associated with increased cardiac angiogenesis in HF
mice
Estrogen has been known to promote angiogenesis in
several tissues, and recently, we have shown that it pro-
motes new blood vessel formation in the heart as well.
We showed that E2 therapy enhanced capillary density
in HF mice and that in the presence of an angiogenesis
inhibitor, E2 could not exert its beneficial action on res-
cuing the heart from failure [5]. Here, we examined the
role of ERα and ERβ in stimulating angiogenesis by E2
in male mice with HF. We have performed immuno-
staining of cardiac cross sections with anti-cluster of
differentiation-31 (CD-31, also known as platelet endo-
thelial cell adhesion molecule-1) antibody, in order to
determine new blood vessel formation. We found that
the capillary density, measured as microvessels per car-
diomyocyte, of HF mice treated with the ERβ-agonist
DPN was similar to that of CTRL (sham-operated mice,
1 ± 0.1 in DPN vs. 0.62 ± 0.06 in HF and 1 ± 0.03 in
CTRL, Fig. 5), while there was no difference in capillary
density between the ERα-agonist PPT and the HF group
(0.58 ± 0.04, Fig. 5b).
Estrogen receptor beta stimulation improves cardiac
hemodynamic parameters in HF mice
We have recently shown that E2-induced rescue of HF
was associated with improved mechanical performance of
the heart, since the rate pressure product (RPP) was sig-
nificantly increased in the group of mice which received
10 days of E2 therapy compared to HF [5]. The cardiac
contraction and relaxation defects induced by HF were
also corrected by E2 therapy, as the maximum rates of LV
pressure rise (dP/dtmax) and decline (dP/dtmin) were atten-
uated with E2 treatment to values similar to healthy hearts
in spite of the sustained presence of the TAC stress stimu-
lus. Here, we examined the role of ERα and ERβ in
E2-induced improvement of hemodynamic parameters in
HF mice. Treatment with the ERβ-agonist DPN was asso-
ciated with improved cardiac hemodynamics, as the RPP
and LVDP of mice in the DPN-treated group were signifi-
cantly improved to 62,261 ± 5963 from 33,530 ± 2663 for
the RPP and to 124.2 ± 7.1 from 86.2 ± 2.7 for the LVDP
versus HF, while PPT treatment had no effect on LV
mechanical performance as the RPP (40,666 ± 2020) and
LVDP (101.9 ± 8.0) were not significantly different from
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HF (Fig. 6a, Table 1). DPN treatment was also associated
with an attenuation of the relaxation and contraction de-
fects induced by HF, as the dP/dtmax and dP/dtmin were
also significantly higher following DPN treatment com-
pared to HF (dP/dtmax from 4871.4 ± 511.9 mmHg/s to
6406 ± 461, and −dP/dtmin from 4298 ± 293 mmHg/s to
5829 ± 322), while PPT had no significant effect on these
parameters (dP/dtmax 4777 ± 203 mmHg/s, and −dP/dtmin
from 3992 ± 196 mmHg/s (Fig. 6b, Table 1).
Discussion
We have recently shown that exogenous E2 therapy start-
ing after the onset of HF rescues HF in male mice (CD-1
as well as C57BL/6) [5]. Here, we examined the contribu-
tion of ERα and ERβ in E2-induced rescue of HF. Our
data using specific ERα and ERβ agonists clearly demon-
strated that ERβ activation is associated with the salutary
effects of E2 in the rescue of HF (Fig. 1). The ERβ-agonist
DPN significantly improved EF of HF mice, while there
was no improvement in the EF of HF mice treated with
the ERα-agonist PPT (Fig. 1). Furthermore, the fact that
E2 failed to rescue HF in the presence of a specific
ERβ-antagonist further confirmed the role of ERβ in
the E2-induced cardioprotection against pressure overload
(Fig. 1). Here we also show that ERβ activation is anti-
hypertrophic, as DPN-treated mice have lower HW/BW
ratio, myocyte CSD, and restored ANF transcript expres-
sion when compared to HF and PPT-treated mice (Fig. 2).
We show that the anti-fibrotic action of E2 in the failing
heart is mediated mainly through ERβ, as treatment with
the ERβ agonist DPN attenuated fibrosis and restored the
expression of profibrotic gene transcripts back to CTRL
(sham) levels, while the ERα agonist PPT had a minimal ef-
fect (Fig. 3). In vitro, DPN fully restored the transcript
levels of the fibrotic markers collagen I and TGF-β1 to
CTRL levels, while PPT had no effect at all (Fig. 4). We
also demonstrated that the improvement of cardiac func-
tion of HF mice treated with DPN, but not PPT, was also
associated with increased cardiac angiogenesis (Fig. 5).
Lastly, here we show that ERβ activation was associated
with improved hemodynamic parameters, and attenuated
contractile defects whereas ERα activation had no signifi-
cant effect (Fig. 6, Table 1).
Role of estrogen receptors in heart function
Both classical estrogen receptors ERα and ERβ as well as
the newly identified E2 receptor G protein coupled re-
ceptor 30 (GPR30) are all expressed in the heart [5, 7, 8,
21]. Among these three E2 receptors, the beneficial role
of ERβ in cardioprotection has been well documented in
the recent years [4, 9, 10]. Female mice lacking the ERβ
gene are less protected against myocardial ischemia/re-
perfusion (I/R) injury compared to wild-type female
mice [22]. Long-term (2 weeks) pre-treatment with the
ERβ-agonist DPN protects the heart against I/R injury in
ovariectomized female mice possibly due to upregulation
of cardioprotective genes, such as those encoding nitric
oxide (NO) biosynthesis and antiapoptotic proteins [9].
Chronic DPN treatment in OVX mice leads to activation
of protein S-nitrosylation and cardioprotection, which was
blocked by nitric oxide synthase (NOS) inhibition [23].
ERβ knockout OVX female mice have abnormal vas-
cular function and hypertension, increased mortality,
and aggravated heart failure [11]. ERβ is also shown to
(See figure on previous page.)
Fig. 3 ERβ-agonist DPN attenuates both interstitial and perivascular cardiac fibrosis in HF mice. a Representative Masson’s Trichrome staining of
LV sections (interstitial, top panels; perivascular, lower panels) in HF mice treated with the ERα-agonist PPT or the ERβ-agonist DPN for 10 days;
blue color indicates fibrosis. b Quantification of overall fibrosis expressed as percentage of each high-power field. c–g Relative transcript expression of
in vivo of profibrotic genes normalized to CTRL (sham-operated mice). GAPDH was used as an internal control (n = 3–6 mice/group). *P < 0.05 vs. CTRL,
**P < 0.001 vs. CTRL, ^P < 0.05 vs. HF, ^^P < 0.001 vs. HF, $P < 0.05 vs. DPN, and $$P < 0.001 vs. PPT
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be responsible for the anti-hypertrophic and anti-fibrotic
effects of E2 in OVX female (22), intact male and female
(27), and intact male mice [10, 24, 25]. Our data using
specific ERα and ERβ agonists clearly demonstrates that
ERβ is the primary receptor responsible for the salutary
effects of E2 in the rescue of HF. Additionally, the fact
that E2 failed to rescue HF in the presence of a specific
ERβ-antagonist further confirms the role of ERβ in
E2-mediated rescue of pressure overload-induced HF.
Similarly, our group has also reported that the protective
action of E2 in intact male rats in the context of right
ventricular failure secondary to pulmonary hypertension
(PH) is also mainly mediated through ERβ [4].
Regarding the role of ERα in the heart, acute activation
of ERα seems to protect the heart from ischemic injury,
while the data is conflicting regarding the role of ERα
under conditions of chronic E2 exposure [26]. Booth et
al. showed that acute pre-treatment with E2 or PPT, but
not DPN, significantly decreased infarct size in an in
vivo OVX female rabbit model of ischemia/reperfusion
injury [27]. Recently, Westphal et al. demonstrated that
specific ERα activation prevents loss of systolic function
in ovariectomized female mice subjected to TAC surgery
[17]. Our data, however, showed no significant improve-
ment in the EF or hemodynamic parameters of HF mice
with PPT treatment (Figs. 1 and 6, Table 1). This dis-
crepancy could be attributed to the different protocol
used. Indeed, Westphal et al. used a prevention protocol
whereas we used a reversal protocol [17]. Thus, it is pos-
sible that ERα activation is not able to reverse
pre-existing HF but can prevent the development of HF.
In our experimental setting, although ERβ activation
significantly increases the EF of HF mice from 33 to
45%, it is not as efficient as E2 in the reversal of
A
B
C
D
Fig. 5 Treatment of HF mice with the ERβ agonist DPN is associated with increased cardiac angiogenesis in HF mice. Confocal images of LV sections
immunostained for CD-31 (a), the overlay of CD-31 and WGA (b), and at higher display magnification of the white squares (c). d Quantification of
capillary density as microvessels per cardiomyocyte. CTRL group was comprised of sham operated mice *P < 0.05 vs. CTRL, ^P < 0.05 vs.
HF, and $P < 0.05 vs. PPT (n = 3–4 animals per group)
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pre-established HF. This difference can be attributed to
the activation of GPR30, as GPR30 has recently been
demonstrated to protect the heart against I/R injury
through inhibition of mitochondrial transition pore
opening [21]. In addition, in vivo activation of GPR30 at-
tenuates diastolic dysfunction and fibrotic deposition as-
sociated with the loss of estrogen in oophorectomized
mRen2.Lewis rats [28].
Role of estrogen receptors in cardiac fibrosis
We have recently shown that E2-induced rescue of HF
in intact male mice is associated with reversal of LV fi-
brosis by reducing the expression of several pro-fibrotic
genes [5]. Lee et al. investigated the expression of the
classic ERs in fibroblasts and found that both ERα and
ERβ were expressed, with the predominant receptor
being ERβ expressed both in the cytosol and nucleus
[29]. Recently, growing evidence demonstrates a distinct
role of estrogen receptors on cardiac fibrosis. For ex-
ample, ERα overexpression in male mice does not pre-
vent development of cardiac fibrosis [30]. However, ERβ
overexpression decreases JNK phosphorylation and pro-
tects intact male and female mouse hearts against fibro-
sis [16]. Furthermore, a recent study highlighted the fact
that ERα activation in fibroblasts increased fibronectin
production [31]. On the other hand, in male mice, ERβ
has been demonstrated to have a beneficial role on car-
diac fibrosis, at least in part by inhibiting TGF-β1 and
collagen I expression in intact male and female mice
(13) and OVX female mice [10, 18]. ERβ is also known
to block the transition of fibroblasts into myofibroblasts.
ERβ-specific activation has been shown to block cardiac
fibrosis by decreasing SMAD3, the downstream target of
TGF-β1 and AngII, which facilitates the transition of fi-
broblasts to myofibroblasts and thus reduces overall fi-
brotic deposition. The same study also demonstrated
that E2 prevented hypertrophy induced by AngII infu-
sion in WT mice, while E2 could not exert any beneficial
effects in ERβ knockout OVX female mice [10]. This
data provides further evidence for the anti-fibrotic and
anti-hypertrophic role of ERβ.
Here, we also show that the anti-fibrotic action of es-
trogen in the failing heart is mediated mainly through
ERβ, as treatment with the ERβ-agonist DPN decreased
fibrosis, as well as effectively restored the levels of the fi-
brotic markers collagen I and TGF-β1 to levels similar
to control in vivo. While the ERα-agonist PPT had a
minimal effect in the reversal of fibrosis in the heart
and was able to decrease the transcript levels of collagen
I and TGF-β1, it was not able to significantly de-
crease the elevated transcript levels of collagen III,
LOX and fibrosin I observed in HF. In vitro, DPN fully
restored the transcript levels of collagen I and TGF-β1
to CTRL levels, while PPT had no effect at all. The dis-
crepancy observed between our in vivo and in vitro data
could be due to the fact that in the working myocar-
dium, we observe the contribution and effect of other
cell types and not just fibroblasts.
Role of E2 receptors in angiogenesis
HF can be attributed, at least in part, to the imbalance
between myocardial oxygen consumption and supply
that will drive the switch from cardiac hypertrophy to
cardiac decompensation and HF [12]. Thus, improving
the blood supply by activating angiogenesis is a critical
aspect in preventing and rescuing HF. E2 has been
shown to be pro-angiogenic in various tissues and or-
gans such as the uterus, breast, brain, and limbs [12–
14]. We have recently shown that E2 could also
A
B
Fig. 6 ERβ-agonist therapy is associated with improved systolic
function and attenuation of contraction and relaxation defects
induced by HF. a RPP was determined right before euthanasia by
direct LV catheterization and was calculated as HR × LVDP where
LVDP = LVSP − LVEDP. b dP/dtMax (maximum rate of the LV pressure
rise, filled bars) and −dP/dtMin (maximum rate of the LV decline)
were directly calculated from the recordings. CTRL group consisted
of sham-operated mice. *P < 0.05 vs. CTRL, **P < 0.001 vs. CTRL,
***P < 0.0001 vs. CTRL, ^P < 0.05 vs. HF, ^^P < 0.001 vs. HF, and
$P < 0.05 vs. PPT (n = 5–7 animals/group)
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stimulate angiogenesis in two different models of HF, in
LV hypertrophy induced by pressure overload as well as
in right ventricular (RV) hypertrophy induced by PH in
intact male and female mice as well as male rats [4, 5].
The cardioprotective action of ERβ is also attributed
in part to stimulation of angiogenesis through activation
of VEGF, basic fibroblast growth factor (bFGF), and
cyclo-oxygenase 2 (COX2). Activation of ERβ by E2 also
leads to increased expression of NOS [32], a well-known
powerful vasodilator, which is also required for angio-
genic properties of vascular endothelial growth factor
(VEGF) [33]. Indeed, in endothelial cell cultures in the
presence of NO antagonist, VEGF failed to promote
angiogenesis [33]. This effect of ERβ on angiogenesis is
reinforced by a positive feedback loop where the prosta-
noids synthetized by COX2 promote VEGF and fibro-
blast growth factor (FGF) expression [34].
Here, we show that, ERβ, but not ERα activation, im-
proves cardiac functional parameters concomitantly with
reducing fibrosis and normalizing blood vessel formation
to levels similar to healthy control mice (Fig. 5). Al-
though ERβ activation was able to normalize angiogen-
esis to levels comparable to CTRL, it was not as potent
as E2 which upregulated angiogenesis ~ 3-fold above
control levels. This could partially account for the lower
EF observed in HF mice treated with DPN compared to
E2 (from ~ 45% in DPN vs. ~ 55% in E2, as we previ-
ously reported [5]). The difference between stimulation
of angiogenesis between E2 and DPN could be due to
the activation of GPR30. Indeed, GPR30 is also known
to promote angiogenesis by activating VEGF [35].
Conclusions
We have recently shown that E2 rescues pre-existing HF
by improving EF from ~ 35 to 55% through stimulating
cardiac angiogenesis and reversing cardiac fibrosis in in-
tact male mice [5]. Here, we demonstrate that ERβ acti-
vation is sufficient to decrease cardiac fibrosis and
restore angiogenesis, as well as to significantly improve
cardiac hemodynamic parameters. Selective agonists for
ERβ such as DPN do not stimulate breast and ovarian
cancer growth and therefore offer a safer alternative for
therapeutic intervention to minimize the unwanted side
effects of E2. Our data highlights the potential clinical
interest of ERβ-specific agonists for the treatment of
chronic heart failure in humans within a relatively safe
time frame, which certainly is a concept that warrants
further investigation.
Abbreviations
ANF: Atrial natriuretic factor; AngII: Angiotensin II; bFGF: Basic fibroblast
growth factor; CD-31: Cluster of differentiation 31; COX2: Cyclo-oxygenase 2;
CSD: Cross-sectional diameter; CTRL: Control; dP/dtmax: Maximum rate of the
LV pressure rise; dP/dtmin: Maximum rate of the LV pressure decline;
DPN: Diarylpropionitrile; E2: Estrogen; EF: Ejection fraction; ERα: Estrogen
receptor alpha; ERβ: Estrogen receptor beta; FGF: Fibroblast growth factor;
GPR30: G protein-coupled receptor 30; HF: Heart failure; HR: Heart rate; HW/
BW: Heart weight to body weight; I/R : Ischemia/ reperfusion; LOX: Lysil
oxidase; LV: Left ventricular; LVEDP: Left ventricular end-diastolic pressure;
LVSP: Left ventricular systolic pressure; NO: Nitric oxide; NOS: Nitric oxide
synthase; NRVM: Neonatal rat ventricular myocytes; PH: Pulmonary
hypertension; PHTPP: 4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-
a]pyrimidin-3-yl]phenol; PPT: 4,4′,4″-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)
trisphenol; RPP: Rate pressure product; RV: Right ventricular; SMAD3: Mothers
against decapentaplegic homolog 3; TAC: Transverse aortic constriction; TGF-
β1: Transforming growth factor-β1; VEGF: Vascular edothelial growth factor;
WGA: Wheat germ agglutinin; WT: Wild-type
Acknowledgements
This work was funded by NIH and NRSA T32-GM065823 and HD00722 (Iorga),
NIH R01HL131182 (Eghbali), and American Heart Association 16GRANT27760058
(Eghbali). We would like to thank Mylene Vaillancourt, M.Sc, for her excellent
technical support with the manuscript revision.
Availability of data and materials
The datasets generated and/or analyzed during the current study are available
from the corresponding author on a reasonable request.
Authors’ contributions
AI was involved in the conception and design of the study, animal treatments,
hemodynamic monitoring, data collection and analysis, interpretation of the
results, and writing of the manuscript. SU was involved in the conception and
design of the study, histochemical analysis of fibrosis, and hemodynamic data
collection and analysis. SU, JL, GR, NM, and SS were involved in the
interpretation of the data and provided intellectual guidance in
manuscript drafting. LA was involved in gene transcript data collection
and analysis as well as cardiac morphometric and fibrosis assessment.
RDN was involved in tissue culture data collection and analysis. JCB
provided hemodynamic data analysis and interpretation. JL performed
the animal surgeries. ME was involved in planning and overseeing all
the experiments and writing and editing the manuscript. All authors
were involved in proof reading the manuscript. All authors read and
approved the final manuscript.
Ethics approval
Animal protocols received institutional review and committee approval.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Anesthesiology, Division of Molecular Medicine,
Cardiovascular Research Laboratories, David Geffen School of Medicine at
University of California Los Angeles, Los Angeles, CA 90095, USA. 2Present
address: Department of Medicine, Division of Gastroenterology/Liver, Keck
School of Medicine of the University of Southern California, Los Angeles, CA
90033, USA. 3Present Address: Wake Forest Institute for Regenerative
Medicine, Wake Forest University, Winston-Salem, NC 27109, USA. 4Present
address: Department of Physiology, University of Texas Health Science
Center, San Antonio, TX 78229, USA.
Received: 18 May 2018 Accepted: 11 October 2018
References
1. Kr C. Heart disease: a textbook of cardiovascular medicine. Philadelphia:
Saunders Company; 1996.
2. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the
prognosis of congestive heart failure: results from the Cardiac Insufficiency
Bisoprolol Study (CIBIS II). Circulation. 2001;103:375–80.
Iorga et al. Biology of Sex Differences            (2018) 9:48 Page 10 of 11
3. Adams KF, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG,
et al. Gender differences in survival in advanced heart failure. Insights from
the FIRST study. Circulation. 1999;99:1816–21.
4. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, et al. Estrogen
rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit
Care Med. 2011;184:715–23.
5. Iorga A, Li J, Sharma S, Umar S, Bopassa JC, Nadadur RD, et al. Rescue of
pressure overload-induced heart failure by estrogen therapy. J Am Heart
Assoc. 2016;5(1).
6. Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, et al.
Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an
estrogen receptor-dependent pathway that increases calcineurin
degradation. Circ Res. 2009;104:265–75 11p following 275.
7. Grohé C, Kahlert S, Löbbert K, Vetter H. Expression of oestrogen receptor
alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol.
1998;156:R1–7.
8. Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L, Stefani E. Heart
estrogen receptor alpha: distinct membrane and nuclear distribution
patterns and regulation by estrogen. J Mol Cell Cardiol. 2006;41:496–510.
9. Nikolic I, Liu D, Bell JA, Collins J, Steenbergen C, Murphy E. Treatment with
an estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell
Cardiol. 2007;42:769–80.
10. Pedram A, Razandi M, O’Mahony F, Lubahn D, Levin ER. Estrogen receptor-
beta prevents cardiac fibrosis. Mol Endocrinol Baltim Md. 2010;24:2152–65.
11. Pelzer T, Loza P-AA, Hu K, Bayer B, Dienesch C, Calvillo L, et al. Increased
mortality and aggravation of heart failure in estrogen receptor-beta
knockout mice after myocardial infarction. Circulation. 2005;111:1492–8.
12. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of
coordinated cardiac hypertrophy and angiogenesis contributes to the
transition to heart failure. J Clin Invest. 2005;115:2108–18.
13. Kyriakides ZS, Petinakis P, Kaklamanis L, Sbarouni E, Karayannakos P,
Iliopoulos D, et al. Intramuscular administration of estrogen may promote
angiogenesis and perfusion in a rabbit model of chronic limb ischemia.
Cardiovasc Res. 2001;49:626–33.
14. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer
involves estrogen and soluble vascular endothelial growth factor receptor 1.
J Natl Cancer Inst. 2004;96:875–8.
15. Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD.
Estradiol regulates angiopoietin-1 mRNA expression through estrogen
receptor-alpha in a rodent experimental stroke model. Stroke. 2005;36:337–41.
16. Mahmoodzadeh S, Leber J, Zhang X, Jaisser F, Messaoudi S, Morano I, et al.
Cardiomyocyte-specific estrogen receptor alpha increases angiogenesis,
Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-
Myocardial Infarction. J Cell Sci Ther. 2014;5:153.
17. Westphal C, Schubert C, Prelle K, Penkalla A, Fliegner D, Petrov G, et al.
Effects of estrogen, an ERα agonist and raloxifene on pressure overload
induced cardiac hypertrophy. PLoS One. 2012;7:e50802.
18. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Kararigas G, et al.
Female sex and estrogen receptor-beta attenuate cardiac remodeling and
apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol.
2010;298:R1597–606.
19. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et
al. Segregation of atrial-specific and inducible expression of an atrial
natriuretic factor transgene in an in vivo murine model of cardiac
hypertrophy. Proc Natl Acad Sci U S A. 1991;88:8277–81.
20. Swildens J, de Vries AAF, Li Z, Umar S, Atsma DE, Schalij MJ, et al. Integrin
stimulation favors uptake of macromolecules by cardiomyocytes in vitro. Cell
Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2010;26:999–1010.
21. Bopassa JC, Eghbali M, Toro L, Stefani E. A novel estrogen receptor GPER
inhibits mitochondria permeability transition pore opening and protects the
heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol.
2010;298:H16–23.
22. Wang M, Crisostomo PR, Markel T, Wang Y, Lillemoe KD, Meldrum DR.
Estrogen receptor beta mediates acute myocardial protection following
ischemia. Surgery. 2008;144:233–8.
23. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-beta activation
results in S-nitrosylation of proteins involved in cardioprotection. Circulation.
2009;120:245–54.
24. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, et al. Abnormal vascular
function and hypertension in mice deficient in estrogen receptor beta.
Science. 2002;295:505–8.
25. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, et al.
Estrogen receptor-beta mediates male-female differences in the
development of pressure overload hypertrophy. Am J Physiol Heart Circ
Physiol. 2005;288:H469–76.
26. Deschamps AM, Murphy E, Sun J. Estrogen receptor activation and
cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med.
2010;20:73–8.
27. Booth EA, Obeid NR, Lucchesi BR. Activation of estrogen receptor-alpha
protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J
Physiol Heart Circ Physiol. 2005;289:H2039–47.
28. Wang H, Zhao Z, Lin M, Groban L. Activation of GPR30 inhibits cardiac
fibroblast proliferation. Mol Cell Biochem. 2015;405:135–48.
29. Lee HW, Eghbali-Webb M. Estrogen enhances proliferative capacity of
cardiac fibroblasts by estrogen receptor- and mitogen-activated protein
kinase-dependent pathways. J Mol Cell Cardiol. 1998;30:1359–68.
30. Du X-J. Gender modulates cardiac phenotype development in genetically
modified mice. Cardiovasc Res. 2004;63:510–9.
31. Aida-Yasuoka K, Peoples C, Yasuoka H, Hershberger P, Thiel K, Cauley JA, et
al. Estradiol promotes the development of a fibrotic phenotype and is
increased in the serum of patients with systemic sclerosis. Arthritis Res Ther.
2013;15:R10.
32. Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA,
Katzenellenbogen BS, Meyer R, et al. Activation of estrogen receptor beta is
a prerequisite for estrogen-dependent upregulation of nitric oxide
synthases in neonatal rat cardiac myocytes. FEBS Lett. 2001;502:103–8.
33. Barnabas O, Wang H, Gao X-M. Role of estrogen in angiogenesis in
cardiovascular diseases. J Geriatr Cardiol JGC. 2013;10:377–82.
34. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A. Vascular endothelial
growth factor is a target gene for estrogen receptor and contributes to
breast cancer progression. Adv Exp Med Biol. 2008;617:437–44.
35. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E,
Abonante S, et al. GPER mediates activation of HIF1α/VEGF signaling by
estrogens. Cancer Res. 2014;74:4053–64.
Iorga et al. Biology of Sex Differences            (2018) 9:48 Page 11 of 11
